The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Key updates and takeaways from the COMMANDS trial
In this video, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, comments on the COMMANDS study (NCT03682536), highlighting the efficacy of luspatercept as a first-line therapy in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS). Responses have been seen across all MDS subtypes, with higher response rates in those patients with a ring sideroblastic phenotype. Prof. Platzbecker notes that quality of life remained stable, with some early fatigue signals improving with continued therapy or dose reductions. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think the data presented at ASH 2024 again confirm the efficacy of luspatercept as a first-line therapy in transfusion-dependent patients with lower-risk MDS, irrespective of the molecular status. So responses are seen actually across all subtypes of MDS with, of course, patients with the ring sideroblastic phenotype having a higher response rate compared to patients without this ring sideroblastic positive phenotype...
I think the data presented at ASH 2024 again confirm the efficacy of luspatercept as a first-line therapy in transfusion-dependent patients with lower-risk MDS, irrespective of the molecular status. So responses are seen actually across all subtypes of MDS with, of course, patients with the ring sideroblastic phenotype having a higher response rate compared to patients without this ring sideroblastic positive phenotype. So I think this still holds, but also a substantial amount of patients had a durable response exceeding a time period of one year. I think that’s great. And this was also significantly higher compared to the current standard of care, which is EPO-ESA-based therapy. In general, the quality of life did not get worse during the treatment course, there were some early signals of more fatigue, but the majority of those patients actually improved significantly with continuation of therapy or sometimes dose reductions. I think the take home message from all of those presentations is a confirmation of the high efficacy, the durability, and also the safety with regards to quality of life.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding.
